Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A post hoc analysis of the SPEARHEAD-1 trial reveals that patients with higher MAGE-A4 expression responded better to afami-cel and lived longer without disease progression, while those with lower baseline tumor burden had significantly better overall survival. The findings could help clinicians identify which synovial sarcoma patients are most likely to benefit from this T-cell therapy — though researchers caution the results need confirmation in larger studies.
A post hoc analysis of the phase 2 SPEARHEAD-1 trial has shed new light on which patients with advanced synovial sarcoma are most likely to benefit from afamitresgene autoleucel (afami-cel), the first FDA-approved engineered T-cell therapy for a solid tumor. Presented at the 2026 SITC Annual Meeting, the analysis found that two key baseline factors — MAGE-A4 tumor antigen expression and tumor burden — independently predicted clinical outcomes.
Among 137 treated patients, those with a MAGE-A4 H-score at or above the median had an overall response rate (ORR) of 53.6% vs. 33.8% for those below the median, and also experienced longer progression-free survival (PFS). Meanwhile, patients with a baseline sum of lesion diameters (SLD) of 10 cm or more faced nearly three times the risk of death compared to those with smaller tumor burden. Notably, sex and prior lines of therapy did not significantly influence outcomes, suggesting afami-cel remains a viable option regardless of these factors.
By the Numbers
Why it matters: As afami-cel gains full FDA approval and broader use, understanding which patients stand to benefit most is critical for treatment planning. These findings suggest that MAGE-A4 expression levels and tumor burden at baseline could serve as practical guides for patient selection — though confirmation in prospective studies is still needed.
